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Abstract
Vascular endothelial growth factor VEGF165 is a critical element for development of the vascular system in physiological and
pathological angiogenesis. VEGF isoforms have different affinities for heparan sulphate proteoglycan (HSPG) as well as for
VEGF receptors; HSPGs are important regulators in vascular development. Therefore, inhibition of interactions between
VEGF and HSPGs may prevent angiogenesis. Here, we demonstrate that an HSPG-binding synthetic peptide, corresponding
to exon 6a-encoded domain of VEGF gene, has anti-angiogenic property. This 20 amino acids synthetic peptide prevents
VEGF165 binding to several different cell types, mouse embryonic sections and inhibits endothelial cell migration, despite its
absence in VEGF165 sequence. Our in vivo anti-tumor studies show that the peptide inhibits tumor growth in both mouse
Lewis-Lung Carcinoma and human Liposarcoma tumor-bearing animal models. This is the first evidence that a synthetic
VEGF fragment corresponding to exon 6a has functional antagonism both in vitro and in vivo. We conclude that the above
HPSG binding peptide (6a-P) is a potent inhibitor of angiogenesis-dependent diseases.
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Introduction
The formation of new blood vessels from pre-existing
vasculature is defined as angiogenesis. The relevance of angio-
genesis is not limited to cancer, but also extends to a number of
non-neoplastic diseases, including macular degeneration, psoriasis,
endometriosis and arthritis [1,2]. Remodeling of blood vessels
occurs through a number of steps. Following destabilization of
existing vessels, it is followed by migration of endothelial cells, and
proliferation and formation of new vessels tubes. Inhibition of this
process can be achieved by blocking any of these stages [3].
Pericytes and lymphocytes release a number of factors which
play important roles in establishing angiogenesis. They include
acidic and basic FGF, tumor necrosis factor TNF-a, transforming
growth factor TGF-b, and most importantly, vascular endothelial
growth factor VEGF. This growth factor exists under several
isoforms, i.e. VEGF121, VEGF165, VEGF189 and VEGF206, which
are generated by alternative mRNA splicing. VEGF isoforms have
different affinities for heparan sulphate as well as for VEGF
receptors, and play distinct roles in vascular development [4–6].
Mast cells secrete heparin which is a linear polysaccharide with
a high sulfate content. It demonstrates pro-coagulant activity.
Heparan sulfate, a closely related molecule, contains much lower
sulfate and is associated with the extracellular matrix (ECM) on
the cell surface of all mammalian cells. It is a component of
heparan sulfate proteoglycans (HSPG) which are attached to the
cell membrane. The composition of polysaccharides and their
sulfation content confers structures on the cell surface which
determine the binding of a number of ligands to the cell surface
[4]. The linear HSPGs binding domain of VEGF is located on
exon 6 [7–9]. However, the interaction of this domain for VEGF
binding to its receptors is poorly understood.
In this study, we used a synthetic peptide, corresponding to exon
6a, to compete VEGF165 binding to cell surface and prevent the
VEGF function both in vitro and in vivo. We found that this
fragment could inhibit VEGF binding to different cell types and
block VEGF-induced endothelial cell migration. Moreover, this
peptide suppressed tumor growth by antiangiogenesis without
causing toxicity. These findings indicate that the 6a-P is a potent
angiogenic inhibitor with potential for clinical investigation.
Results
In order to test the specificity of antiangiogenesis efficacy of
HSPG binding site of VEGF, we used a 20-amino acid synthetic
peptide, called 6a-P which is encoded on exon-6a domain of the
human VEGF gene (Materials and Methods). The mouse version of
this peptide shows a single amino acid substitution at tyrosine by
phenylalanine.
6a-P peptide binds strongly to heparin and prevents
VEGF165 binding to different cell types by FACS
VEGF is an important angiogenesis factor, not only for
endothelial cells but also tumor cells. The binding of VEGF to
PLoS ONE | www.plosone.org 1 April 2010 | Volume 5 | Issue 4 | e9945endothelial cell surface is mediated by HSPG. To test binding of the
peptide 6a-P to proteoglycans, we employed a small heparin-
sepharose column for binding studies. Most of the peptide was
eluted at concentration of 1 molar NaCl as indicated in Table 1. In
order to investigate the interactions between VEGF and HSPG,
several cell lines such as HUVECs, liposarcoma cells, pancreatic
cancer cells (ASPC-1) and mouse LLC were used for human
recombinant VEGF165 (rhVEGF) binding by flow cytometry
analysis (FACS). 0.1 or 1 mg/ml rhVEGF was used for incubation
of the cells in the presence and absence of the peptide. The HSPG
binding peptide blocked VEGF binding to human liposarcoma
cells, ASPC-1 cells to more than 99% and VEGF binding of
HUVECs to 96% at high concentration (10 mg/ml) (Fig. 1A).
VEGF-Trap is a reagent which contains the neutralizing binding
domains of the two VEGF receptors FLT-1 and KDR, and it is
employed as an antiangiogenic therapy in ongoing clinical trials. It
functions by competing with VEGF receptors [10]. It inhibits
VEGF binding to HUVECs by approximately 70%. The synergic
experiment showed that the VEGF binding was inhibited
completely when 6a-P plus VEGF-Trap were present in binding
media of HUVECs (Fig. 1B) and human liposarcoma cells
(Supplemental Figure S1). We also used two synthetic linear
peptides corresponding to exons 7 and 8 (cysteines were substituted
by alanines), which comprise the heparin binding region of
VEGF165 (designated HP165-A and HP165-B). The results showed
that these two linear peptides were not capable of blocking VEGF
binding to cells even at high concentration, pointing to requirement
for maintaining three dimensional structure of VEGF165 heparin
binding region (Fig. 1C).
Immunocytochemistry data demonstrate that the 6a-P
decreases VEGF165 binding to the cell surface
Immunocytochemistry experiments confirmed that VEGF
binding was also inhibited by the 6a-P peptide. The VEGF
binding intensity on endothelial cells (HUVECS) was decreased
when the 6a-P peptide or VEGF-Trap were present (Fig. 2A).
Similar results were observed with human liposarcoma cells
(Fig. 2B). The VEGF intensity showed a decrease in a dose-
dependent manner by the presence of the HSPG binding peptide.
VEGF binding activity was also inhibited by VEGF-Trap which
served as a positive control (Fig. 2B). Furthermore, ex vivo mouse
brain embryonic sections were used to confirm this phenomenon
in E14.5 mice brain. VEGF binding activity was blocked by 6a-P
in embryonic mouse brain, lung and kidney (Supplemental Figure
S2). These results indicate that the HSPG binding domain play an
important role for VEGF interactions on the surface of the cells.
6a-P peptide inhibits endothelial cells migration
Endothelial cell migration is an important step in new blood
vessel formation and tumor angiogenesis. To evaluate the effective
of HSPG binding peptide in endothelial cell migration, we used
rhVEGF165 to induce HUVECs migration in a transwell assay
(Materials and Methods). We monitored and quantified the
migration of cells. Cells migrating across the membrane were
stained with blue-purple stain (Fig. 3A) and counted (Fig. 3B). The
6a-P peptide inhibited VEGF-induced endothelial cell migration
at two different concentrations (P,0.001).
6a-P peptide inhibits angiogenesis and suppresses tumor
growth in vivo
Our animal experiments enable us to evaluate the efficacy of 6a-
P peptide by inhibiting angiogenesis and tumor growth in vivo. For
these studies, we used two different tumor-bearing animal models.
Mice were treated with peptide or PBS twice a day. In the mouse
LLC animal model, we found that tumor sizes were decreased on
average about 30% at the end of treatment (Fig. 4A). However, the
tumor weights showed about a 40% difference between treated
and control groups (Fig. 4B). The human liposarcoma animal
model showed tumor size was decreased approximately 36% in
high dose treated group (Fig. 4C). Less hemorrhage (shown in red
on tumor surface) was observed at the high dose of peptide
treatment, even though tumor masses were in some cases similar in
size to those of the control mice (Fig. 4D). The tumor weights on
average were reduced 2-fold following treatment (Fig. 4E). We
monitored the mouse body weights twice weekly in order to detect
signs of toxicity. Peptide-treated and PBS-treated groups showed
similar body weights at the end of the experiment with no
significant statistical difference (data not shown).
Tumor vessel activity and tumor cells apoptosis are
affected by 6a-P peptide
Vessel activity is another important factor for angiogenesis
in tumor. VEGF165 is secreted from cells and binds with high
affinity to the two receptors on endothelial cells, FLT-1 and
KDR [11–13]. FLT-1, KDR are almost exclusively expressed on
endothelial cells [14] and appear to have different functions with
respect to stimulating endothelial cell proliferation, migration, and
differentiation [15,16]. To verify the inhibition of VEGF complex
with its receptor by 6a-P peptide, we used the monoclonal
antibody Gv39M (Materials and Methods) to recognize VEGF/
KDR complex in both peptide and PBS-treated xenograft animals.
Immunohistochemistry results showed that VEGF/KDR com-
plexes were colocalized with VWF on PBS-treated tumor (Fig. 5A:
arrow on up panel). However, the staining signal was clearly
decreased after peptide treatment (Fig. 5A: arrow on lower panel).
The number of apoptotic cells is additional evidence for
verifying that 6a-P peptide is capable of suppressing tumor growth
in vivo. The TUNEL assay showed more apoptotic cells in treated
than non-treated group of tumors (Fig. 5B).
Discussion
A single gene is responsible for generation of alternative splice
forms of VEGF. Exons 1-5 of VEGF contain sequences which
determine the protein sequences required for the recognition of its
tyrosine kinase receptors, FLT-1 and KDR [17–21]. Exons 6 and
7 encode peptide domains which are responsible for two separate
different heparin-binding regions on the cell surface. In general,
different VEGF isoforms are distinguished by the presence of
heparin- binding sequences belonging to one of the targeted
HSPGs. VEGF121 does not bind to ECM due to its lack of heparin
Table 1. 3.5 mg of peptide 6a-P was dissolved in 1 ml of
25 mM Tris, 0.15 M NaCl, pH=7.4.
NaCl concentration A280
Flowthrough 0.02
0.15 M wash 0.05
0.5 M 0.148
1 M 0.561
2 M 0.016
It was applied to a column containing 1 ml of heparin-sephalose (GE-
Healthcare). 2 ml step salt gradient (containing 25 mM Tris, pH 7.4) was
employed for elution. Absorption at 280 nm reflects concentrations of the
peptide.
doi:10.1371/journal.pone.0009945.t001
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PLoS ONE | www.plosone.org 2 April 2010 | Volume 5 | Issue 4 | e9945Figure 1. 6a-P peptide prevents VEGF binding to different cell types by FACS analysis. HUVECs, fibroblasts, AsPC-1 and liposarcoma cells
were subjected to FACS analysis. Cells were digested and resuspensed with 2% BSA in PBS for blocking, 0.1 mg/ml rhVEGF was incubated and present
or absent with 1 (low dose) or 10 (high dose) mg/ml of the peptide for 1 h in 4uC. After cold PBS washing, the samples were incubated with VEGF
antibody and secondary FITC-labeled antibody. The results show that rhVEGF binding activity is inhibited when the peptide is present (A). VEGF-Trap
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whereas VEGF189 contains both exon 6a and exon 7. Finally,
VEGF206 contains both exons 6a and 6b of the VEGF gene.
VEGF 121 and VEGF165 are secreted into the medium by
producing cells, whereas VEGF189 and VEGF206 are sequestered
by cell surface heparan sulfates [19,22–24]. However, the
contribution of exon 6a to the biological properties of VEGF
has not been studied in detail.
In this report, we investigated a synthetic peptide corresponding
to the exon 6a-encoded domain of VEGF gene, which is known as
an ECM or heparin-binding region. We found that the VEGF165
binding to cell surface was blocked by this peptide in a competitive
binding study by FACS (Fig. 1) and immunocytochemistry (Fig.2).
The functional analysis showed that it inhibited endothelial cell
migration in a dose-dependent manner (Fig. 3). For comparison
purposes, we employed two synthetic peptides corresponding to
exons 7 and 8, which comprise the heparin binding region of
VEGF165 (designated HP165-A and HP165-B). This region
contains several disulfides which are probably important for the
heparin binding properties of VEGF165 [25]. In order to confer
solubility to the peptides, we replaced the cysteins by alanines. The
results showed that the two modified peptides were not capable of
blocking VEGF binding to cells even at high concentration
(Fig. 1C), pointing to importance of secondary structure and
formations of proper disulfides for such an interaction.
Our animal experiments demonstrated that the tumor masses
had fewer blood vessels present on tumor surfaces after low or
high concentrations of the peptide treatment (Fig. 4D). VEGF
has been used for a positive control, inhibiting VEGF binding about 70%. The synergic result shows that the rhVEGF binding is inhibited completely
when 1 mg/ml of the peptide plus 0.1 mg/ml of VEGF-Trap are present with HUVECs (B). HP165A, HP165B peptides do not inhibit binding of VEGF to
HUVECs (C).
doi:10.1371/journal.pone.0009945.g001
Figure 2. 6a-P peptide decreases VEGF binding activity to cell surface by immunocytochemistry. Immunocytochemistry was used to
confirm the FACS results. VEGF (0.1 mg/ml) binding intensity on HUVECS is decreased when the peptide (1 mg/ml) or VEGF-Trap (0.1 mg/ml) are
present (A) (Bar, 20 mm). Similar result is shown on human liposarcoma. VEGF intensity is decreased in dose-dependent manner by 6a-P peptide (B)
(Bar, 20 mm).
doi:10.1371/journal.pone.0009945.g002
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are found in most solid tumors. Up-regulation of both the ligand
and its receptor, specifically in tumor sections, leads to a high
concentration of VEGF:receptor complex on tumor endothelium,
as compared with the endothelium in normal tissue [11]. Our
results showed that the interaction of VEGF and its recep-
tor, KDR, was suppressed when this peptide was present
(Fig. 5A).
Proteoglycans are associated with the mammalian cell mem-
brane. Their genetics have been studied in detail in Drosophila
melanogaster and Caenorhabditis elegans. Gradient formation and signal
trasnductions are to a great extent modulated by HSPGs [6,26–28].
Several prominent signaling cascades are disrupted by mutations in
these acidic glycoproteins [29–31]. In support of this possibility, our
HSPG binding peptide treated tumor section showed an increase
in apoptotic cells (Fig. 5B). It may explain the phenomenon of
angiogenic and tumor growth suppression observed in animals
treated with exogenous 6a-P peptide, resulting in competition with
endogenous VEGF binding to its targets. Our peptide, although
based onitssequence,appearstobe ofa more non-specificnature,it
is capable of competing with binding between VEGF165 and its
heparin binding domain. We found that the 6a-P peptide could not
only block VEGF binding and inhibit its function on the cells, but
also suppress tumor growth and angiogenesis in animal models.
These results serve as evidence that HSPG domain of exon 6a may
play an important role in regulating VEGF function and its
signaling transduction pathway.
In summary, we showed in this study that 6a-P peptide
corresponding to exon 6a inhibited, in a concentration-dependent
manner, the binding of VEGF165 to endothelial cells and tumor
cells and VEGF-induced endothelial cell migration. It also blocked
angiogenesis in the matrigel assay and suppressed tumor growth in
tumor-bearing mice models. Moreover, we have demonstrated
that VEGF/KDR complex formation was decreased and the
apoptotic cells were increased after peptide treatment. This VEGF
inhibitor may be a potential lead compound for the development
of therapeutic agents against tumor angiogenesis or angiogenesis-
dependent diseases.
Materials and Methods
Cell lines and materials
The cell lines: human Liposarcoma (a gift from Dr. George
Naumov), human pancreatic cancer ASPC-1 (ATCC), mouse
LLC (ATCC) were cultured in DMEM or RPMI 1640 with L-
glutamine, respectively, and supplemented with 10% FCS and
antibiotics. HUVECs (Lonza) were maintained in EBM endothe-
lial growth media and EGM Bullet Kit (Lonza) with antibiotics.
VEGF-Trap was a gift from Regeneron Pharmaceuticals Corpo-
ration (Tarrytown, NY). The 6a-P peptide ‘‘KSVRGKGK-
Figure 3. 6a-P peptide inhibits endothelial cells migration. HUVECs were plated into inserts (8 mm pore size) of 24-well transwell plate and
duplicated. The lower chamber was filled with serum free EBM medium containing 50 ng/ml rhVEGF plus different concentrations of the peptide for
16 h. The results show that endothelial cells migrating across the membrane are suppressed by the peptide in dose-dependent manner (A). VEGF
induces endothelial cell migration is inhibited almost 90% when peptide is present at high concentration (B; P,0.001).
doi:10.1371/journal.pone.0009945.g003
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binding peptides, HP165A ‘‘RRKHLFVQDPQTAKCSAK-
NTD-SRAKAR’’ and HP165B ‘‘KARQLELNERTARADKP-
RR’’ were synthesized by Synpep Corp. (Dublin, CA)
Flow-cytometry analysis of VEGF binding on cell-surface
Different cells were trypsinized and resuspended in cold 2% BSA
in PBS for 30 min at 4uC, and incubated with 0.1,1 mg/ml
recombinant human VEGF (rhVEGF) (R&D). After cold PBS
washing, the samples were incubated with Avastin (an antibody
against VEGF produced by Genentech) followed by the secondary
FITC-labeled antibodies (Sigma) and analyzed by BD Biosciences
FACS Calibur flow cytometer.
Immunocytochemistry
The in vitro staining of HUVECs and Liposarcoma cells were
plated on cover slips or the ex vivo staining of mouse embryonic
frozen section E14.5 slides were fixed by 4% paraformaldehyde for
10 min. Cells or sections were incubated with 100 ng/ml of
rhVEGF present or absent with 1 or 10 mg/ml synthetic heparin-
binding peptide for 1 h. After PBS washed, the slides were
detected by Avastin and Alexa 488-labeled IgG. The slides were
Figure 4. Angiogenesis and mouse LLC tumor growth are suppressed by 6a-P peptide in vivo. Two different tumor-bearing animal
models were employed for anti-tumor study. The mice were treated with the peptide or PBS twice a day after tumor cells injection. In mouse LLC
animal model, the tumor sizes are decreased about 30% after the treatments (n=5) (A). However, the tumor weights show about 40% different
between treated or non-treated groups (B). Human liposarcoma animal model shows the tumor sizes are decreased about 36% in high dose treated
group (C). Less hemorrhage (as shows in red on tumor surface) is observed in the high dose of peptide treated despite similarities in tumor sizes for
treated and untreated mice (D). The tumor weights show a difference of 2-fold following treatment (n=8) (E).
doi:10.1371/journal.pone.0009945.g004
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or Hoechst33258 counterstaining of nuclei are shown in blue.
Endothelial cell migration assay
HUVECs were washing by serum free EBM medium twice and
re-suspended containing 5610
4 cells/well in 0.6 ml with medium
were plated into 24-well inserts (Coring, 8 mm pore size) in
duplicatation. The lower chamber was filled with 0.6 ml of serum
free EBM medium containing 50 ng/ml rhVEGF (R&D) plus
different concentrations of 6a-P peptide. After incubation for 16 h
at 37uC, the cells were fixed by methanol and stained with eosin
and hemotoxlin. Cells on the upper side of the transwell
membrane were removed by cotton swab. Cells migrating to the
lower side of membrane were counted.
Animal and tumor models
All animal procedures were carried out in compliance with
Children’s Hospital Boston guidelines. Protocols were approved by
the Institutional Animal Care and Use Committee. Eight weeks
old male and pregnancy female C57B/6J mice (The Jackson
Laboratory) and SCID mice (Massachusetts General Hospital)
were used. Mice were acclimated, caged in groups of five in a
barrier care facility, and fed animal chow and water ad libitum
and all mice were shaved and the dorsal skin was cleaned with
ethanol before cells injection. Human liposarcoma or mouse LLC
cells were used for anti-tumor studies. A suspension of 5610
6 of
liposarcoma or 1610
6 of LLC cells in 0.1 ml of PBS was injected.
Mice were weighed and tumors were monitored twice a week in
two diameters with digital calipers. Tumor volumes were
determined using a
26b60.52 (where a is the shortest and b is
the longest diameter). Tumors were allowed to grow to
,100 mm
3 and mice were randomized. The treatments were by
bolus s.c. injections twice a day.
Immunohistochemistry and TUNEL assay
Tumors, organs and E14.5 embryo were embedded in OCT
medium (EMS). Sections were rinsed by cold PBS and fixed with
4% paraformaldehyde for 10 min before staining. Apoptosis was
examined by use of the terminal deoxynucleotidyltransferase-
mediated deoxyuridine triphosphate nick end labeling (TUNEL)
assay [32] through the manufacturer’s protocol (Promega).
Antibody von Willebrand Factor (Dako) was used for vessels
staining. Gv39M (a gift from Dr. Philip E. Thorpe) was used for
VEGF:KDR complex staining [33]. The primary antibodies were
detected by Alexa 488 or 594-labeled secondary antibodies
(Molecular Probes). The sections were imaged by confocal-
microscopy (model DM IRE2; Leica). For tumor vessel density,
VWF positive staining was counted in five fields by pixels number.
Data are expressed as mean 6SD.
Statistical method
Data are expressed as mean 6 SD. We considered a P value
below 0.05 as significant by using two-sided unpaired Student’s t
test.
Supporting Information
Figure S1
Found at: doi:10.1371/journal.pone.0009945.s001 (0.25 MB TIF)
Figure S2
Found at: doi:10.1371/journal.pone.0009945.s002 (2.41 MB TIF)
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